Rectovaginal fistula in a cervical cancer patient treated with sequential radiotherapy and bevacizumab: A dose‐volume analysis

Abstract

Abstract Bevacizumab is a monoclonal antibody against vascular endothelial growth factor that exerts antitumor effect by preventing tumor angiogenesis. Gastrointestinal fistula is a common side effect of bevacizumab in combination with radiotherapy. This case of rectovaginal fistula indicates that the side effect may be unpredictable by the conventional dose‐volume parameters for the rectum.

Keywords

• bevacizumab
• cervical cancer
• dose‐volume analysis
• radiation
• rectovaginal fistula